GlassScriptPhysician profile
Kyung Nam Kim
NPI 1457391773
$1,371.70
in general payments reported to CMS, 2019-2025
14 companies · $37.44 in 2025
The $37.44 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $464 · 2021: $560 · 2022: $149 · 2023: $132 · 2024: $28.77 · 2025: $37.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $132 · Food and Beverage: $66.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $131.75 |
| Food and Beverage | $66.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $378.89 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $198.95 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $150.47 | 2020-2021 | |
| Janssen Biotech, INC. | $113.29 | 2020-2021 | |
| Clovis Oncology, INC. | $99.95 | 2020 | |
| Amgen INC. | $95.00 | 2020 | |
| Pfizer INC. | $79.71 | 2021-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $52.51 | 2020-2021 | |
| Incyte Corporation | $48.12 | 2020 | |
| Array Biopharma INC | $37.44 | 2025 | Braftovi, Tukysa, Mektovi |
| Genzyme Corporation | $33.35 | 2022 | |
| Astellas Pharma US INC | $31.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $28.77 | 2024 | |
| Lilly USA, LLC | $23.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyung Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.